Literature DB >> 6572078

The secretion of plasminogen activators by human myeloid leukemic cells in vitro.

E L Wilson, P Jacobs, E B Dowdle.   

Abstract

Peripheral blood cell preparation from 23 normal subjects and 72 patients with acute and 32 patients with chronic myeloid leukemia were cultured in vitro and released plasminogen activators were analyzed. The quantity of plasminogen activator secreted by leukemic cells varied widely and could not be correlated with the clinical severity of the disease. Immunochemical and electrophoretic techniques have been used to show that normal peripheral blood granulocytes released exclusively urokinase-like plasminogen activator, whereas leukemic cells secreted either urokinase or a tissue activator-like enzyme. The molecular species of enzyme released by acute myeloid leukemic cells may serve as a diagnostic marker of relevance to the management of this disease, since patients with acute myeloid leukemia whose cells released only tissue plasminogen activator did not respond to combination chemotherapy. Tissue plasminogen activators released by leukemic cells may display an unusual electrophoretic pattern that resembles that shown by urokinase. Immunochemical procedures are therefore essential for the correct identification of these enzymes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6572078

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Human tissue-type plasminogen activator gene located near chromosomal breakpoint in myeloproliferative disorder.

Authors:  T L Yang-Feng; G Opdenakker; G Volckaert; U Francke
Journal:  Am J Hum Genet       Date:  1986-07       Impact factor: 11.025

2.  Cutaneous infiltrates of histiocytosis X contain plasminogen activator-bearing epidermotropic dendritic cells different from Langerhans cells.

Authors:  G Burg; K G Stünkel; T Bieber; U Opitz; P Kaudewitz
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

Review 3.  Acute promyelocytic leukaemia in the all trans retinoic acid era.

Authors:  T G DeLoughery; S H Goodnight
Journal:  Med Oncol       Date:  1996-12       Impact factor: 3.064

4.  Hemostatic and fibrinolytic parameters in patients with acute myeloid leukemia: activation of blood coagulation, fibrinolysis and unspecific proteolysis.

Authors:  W Speiser; I Pabinger-Fasching; P A Kyrle; S Kapiotis; A Kottas-Heldenberg; P Bettelheim; K Lechner
Journal:  Blut       Date:  1990-11

5.  Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases.

Authors:  F O Akenami; V Sirén; M Koskiniemi; M A Siimes; H Teräväinen; A Vaheri
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

6.  An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines.

Authors:  A R Nusrat; H A Chapman
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

7.  Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2.

Authors:  Elena Ortiz-Zapater; Sandra Peiró; Oriol Roda; Josep M Corominas; Susana Aguilar; Coral Ampurdanés; Francisco X Real; Pilar Navarro
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

Review 8.  Fibrinolytic mechanisms in tumor growth and spreading.

Authors:  T Südhoff; W Schneider
Journal:  Clin Investig       Date:  1992-08

Review 9.  The plasminogen-plasmin system in malignancy.

Authors:  H C Kwaan
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 10.  Clinical disorders of fibrinolysis: a critical review.

Authors:  R B Francis
Journal:  Blut       Date:  1989-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.